Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kavibrain Suspension is an oral pediatric nutraceutical product from Kaviva formulated as a multi-ingredient nutritional suspension containing l-carnosine, eicosapentaenoic acid, docosahexaenoic acid, and vitamin D3. It is marketed as nutritional brain support intended to support brain development, cognitive function, neural health, and general neurodevelopmental nutrition, particularly in children with autism spectrum disorder, learning difficulties, speech delay, attention concerns, and developmental delay. Its proposed mechanism is non-target-specific nutritional supplementation: l-carnosine is positioned as a neuronal support and antioxidant nutrient, while the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and vitamin D3 are intended to provide membrane, neurodevelopmental, and micronutrient support rather than acting as a conventional pharmaceutical targeted therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kavibrain Suspension.